DDIT3 and diffuse large B-cell lymphoma: Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin common lymphoma worldwide accounting for about 30% of newly diagnosed cases in the United States.[10] Although most patients achieve complete remission in response to the current frontline therapy, R-CHOP, approximately 40% of patients fail to respond to initial treatment and eventually die of disease.[11] So far, many signal transduction pathways have been implicated in the pathogenesis of DLBCL such as the BCR signaling, [12] NF-κB [13], [14] and mTOR pathways.